Found vs LifeMD (2026): prices, structure, verdict

On tirzepatide, Found is cheaper: $289 versus $597 a month all-in — a $308 monthly gap, $3,696 across a year of maintenance dosing.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

On semaglutide, Found is cheaper: $289 versus $348 a month all-in — a $59 monthly gap, $708 across a year of maintenance dosing.

§ Side by side

§ Each record, read aloud

The two records, condensed

Found: the record, condensed

Found’s tirzepatide program bills $289 a month once every mandatory fee is counted, measured at the 10 mg maintenance basis. Because pricing is flat across the ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)), a dose increase at Found is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

There is no membership line. $289 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

Context for that figure: it ranks #6 of 17 in the verified tirzepatide index — $74/month above the floor (NexLife↗, $215) — and sits $160 under the brand benchmark (Zepbound (LillyDirect↗), $449 at maintenance). Annualized, a monthly-billed year here runs $3,468.

Start with the load-bearing figure: $289 a month, all-in, is what Found charges for semaglutide at the 2.4 mg basis. It is a flat structure: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

To place the number: #15 of 20 verified programs, with the floor $156/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare↗)) sits at $349, so the compounded case here is worth $60 a month. A year at this figure: $3,468 monthly-billed.

Operationally at Found: shipping included; commitment none month-to-month; prepaid terms for lowest rate; cancellation membership recurs; prepaid terms are paid up front; pharmacy not publicly named — ask in writing before paying; states: most states; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Found page · visit Found ↗

LifeMD: the record, condensed

LifeMD’s tirzepatide program bills $597 a month once every mandatory fee is counted, measured at the 10 mg maintenance basis. Because pricing is flat across the ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)), a dose increase at LifeMD is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

Inside that $597 sits a mandatory $149-a-month membership. We fold it in automatically — the medication-only figure the marketing may lead with is $448, and it is not a price anyone can actually pay, because the membership cannot be declined.

Context for that figure: it ranks #17 of 17 in the verified tirzepatide index — $382/month above the floor (NexLife, $215) — and sits $148 over the brand benchmark (Zepbound (LillyDirect), $449 at maintenance). Annualized, a monthly-billed year here runs $7,164.

LifeMD’s semaglutide program bills $348 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. The price is dose-flat: the standard titration ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg) is financially invisible here, because the top rung bills exactly what the bottom rung billed. That converts the advertised number from a floor into a ceiling — the strongest single structural feature a program in this category can have.

Inside that $348 sits a mandatory $149-a-month membership. We fold it in automatically — the medication-only figure the marketing may lead with is $199, and it is not a price anyone can actually pay, because the membership cannot be declined.

To place the number: #20 of 20 verified programs, with the floor $215/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare)) sits at $349, so the compounded case here is worth $1 a month. A year at this figure: $4,176 monthly-billed.

Operationally at LifeMD: shipping included; commitment program fee recurs monthly; cancellation program fee recurs until cancelled; pharmacy not publicly named — ask in writing before paying; states: 50 states; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the LifeMD page · visit LifeMD ↗

Tirzepatide: the duel in full

The tirzepatide arithmetic between these two is short: $289 (Found) against $597 (LifeMD). $308 a month sounds survivable; $3,696 a year is a decision.

Both figures are dose-flat, which is the cleanest possible comparison: two ceilings, no titration surprises on either side, and the $308 gap is exactly what it appears to be.

LifeMD’s total includes a mandatory $149/month membership; Found has none. The all-in figures above neutralize that difference — but the membership side has an exit consideration the other lacks: a fee that recurs until you affirmatively cancel it.

Semaglutide: the duel in full

Put the two semaglutide figures side by side and hold them there: Found at $289, LifeMD at $348 — a $59 monthly spread that compounds to $708 over a maintenance year and $1,416 over two.

Both figures are dose-flat, which is the cleanest possible comparison: two ceilings, no titration surprises on either side, and the $59 gap is exactly what it appears to be.

LifeMD’s total includes a mandatory $149/month membership; Found has none. The all-in figures above neutralize that difference — but the membership side has an exit consideration the other lacks: a fee that recurs until you affirmatively cancel it.

Translate the $308/month spread into medication: $3,696 a year equals roughly 12.8 months of therapy at the cheaper program’s rate. That is the honest unit for gaps in this market — months of treatment, not abstract dollars — and it is why small-looking monthly differences decide long courses.

On best published rate — the lower of each program’s month-to-month price and its labeled 12-month-plan rate, which is the sort most price roundups quietly run — the duel reads: Found $289/mo month-to-month versus LifeMD $597/mo month-to-month. Same winner on both bases — Found leads whether you compare month-to-month prices or committed-plan rates, which makes this one of the cleaner verdicts in the index. Prepaid rates are upfront commitments with refund terms to verify before they count.

§ The clock, run forward

Three, six, twelve, twenty-four months — best path each way

3 months: Found $867 monthly; LifeMD $1,791 monthly — best path favors Found by $924. 6 months: Found $1,734 monthly; LifeMD $3,582 monthly — best path favors Found by $1,848. 12 months: Found $3,468 monthly; LifeMD $7,164 monthly — best path favors Found by $3,696. 24 months: Found $6,936 monthly; LifeMD $14,328 monthly — best path favors Found by $7,392.

Prepaid paths above are billed upfront and assume the published rate holds (the 24-month figures extend the 12-month rate, an assumption worth naming). The honest reading: over short horizons the monthly gap decides; over long horizons the prepaid ladders and structural traps (dose tiers, memberships) take over — which is exactly the split the verdict section below scores.

The same clock, on semaglutide

3 mo: Found $867 vs LifeMD $1,044 — $177 to Found. 6 mo: Found $1,734 vs LifeMD $2,088 — $354 to Found. 12 mo: Found $3,468 vs LifeMD $4,176 — $708 to Found. 24 mo: Found $6,936 vs LifeMD $8,352 — $1,416 to Found.

Same rules as above: prepaid figures are upfront commitments, and the 24-month lines extend the 12-month rate as a stated assumption. Where the two molecules crown different winners between these two programs, that split is itself the finding — molecule choice and provider choice are separate decisions.

§ Structure vs structure

Everything besides the price

Coverage: Found publishes “most states”; LifeMD publishes “50 states” — for anything short of an explicit 50-state claim, intake is the final word.

Neither names its pharmacy publicly — the single most useful disclosure in this category, missing on both sides; ask each, in writing, before paying either.

Exit terms: Found — none month-to-month; prepaid terms for lowest rate; membership recurs; prepaid terms are paid up front. LifeMD — program fee recurs monthly; program fee recurs until cancelled.

Evidence: Found third-party reported (captured 2026-08-05); LifeMD third-party reported (2026-08-05).

A rule that has held across this index: disclosure predicts disclosure. Whichever of these two publishes more — pharmacies, states, exit terms — is usually the one whose invoice matches its ad.

In the full tirzepatide index these two sit at #6 and #17 of 17: between them lie 10 other programs, and the whole ladder is at cheapest tirzepatide providers. In the full semaglutide index these two sit at #15 and #20 of 20: between them lie 4 other programs, and the whole ladder is at cheapest semaglutide providers.

§ If you move

Switching between Found and LifeMD

Prescriptions do not transfer like phone numbers: moving in either direction means completing the destination’s intake and having its prescriber write a new patient-specific prescription. The mechanics that prevent a bad month: confirm the destination serves your state and quotes your current dose in writing before cancelling anything; time the first new shipment to overlap the last old one rather than gap it; cancel the origin per its published terms (Found: membership recurs; prepaid terms are paid up front; LifeMD: program fee recurs until cancelled) and screenshot the confirmation; and never leave a prepaid balance stranded — which is the standing argument for prepaying only after a program has already earned a few monthly cycles.

§ Verdict by situation

Which one, for whom

§ More pairings